EcoDrugPlus

Mitogen-Activated Protein Kinase 14b

Ensembl ID : ENSIPUG00000023950
Gene Symbol: MAPK14B
3 Cross references
83 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSIPUG00000016591
Gene Symbol: MAPK3
4 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSIPUG00000000278
Gene Symbol: MAPK8A
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSIPUG00000013682
Gene Symbol: MAPK8B
4 Cross references
225 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSIPUG00000020042
Gene Symbol: MAPK9
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSIPUG00000001241
Gene Symbol: MAP2K2A
4 Cross references
212 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSIPUG00000019152
Gene Symbol: MAP2K2B
2 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1, E3 Ubiquitin Protein Ligase

Ensembl ID : ENSIPUG00000001768
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSIPUG00000012119
Gene Symbol: LOC108264755
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSIPUG00000011483
Gene Symbol: MAP3K11
4 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSIPUG00000024813
Gene Symbol: MAP3K12
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSIPUG00000006876
Gene Symbol: SI:CH211-45C16.2
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).